IP Library Granted Patent US 8,518,681
Granted Patent B2
US 8,518,681 · App. 12/941,868 · Granted Aug 27, 2013

Selective lysing of cells using ultrasound

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,518,681
App. No.
12/941,868
Granted
Aug 27, 2013
Kind
B2
Abstract

Described are embodiments that employ ultrasonic energy to selectively lyse larger adipose cells in a suspension containing adipose cells of different sizes resulting in a suspension in which the only viable cells are the small adipose cells and stem cells. Embodiments provide for generating an acoustic standing wave field of sufficient intensity and proper geometry, that high shear stress is induced on the cell membranes of cells larger than a predetermined size. The remaining small adipose cells can be physically separated from the suspension after the suspension is subjected to the acoustic standing wave field.

Claims (30)

1. A method for lysing adipose cells of diameters equal to or greater than a predetermined diameter, the method comprising:

generating an acoustic standing wave field, wherein the geometry of the acoustic standing wave field is such that one half of the wavelength of the acoustic standing wave field is less than or equal to the predetermined diameter, and wherein the intensity of the acoustic standing wave field is sufficient to cause lysing of adipose cells of diameters equal to or greater than the predetermined diameter; and

subjecting a mixture of adipose cells and stem cells to the acoustic standing wave field to generate a lysed mixture, wherein the mixture of adipose cells and stem cells includes at least some adipose cells having a diameter equal to or greater than the predetermined diameter.

2. The method of claim 1 , wherein the subjecting results in selective lysing of adipose cells equal to or greater than the predetermined diameter compared to cells of a smaller diameter.

3. The method of claim 1 , wherein the acoustic standing wave field is an ultrasonic standing wave field.

4. The method of claim 1 , further comprising:

processing the lysed mixture to prepare at least a portion of the lysed mixture for injection into a patient.

5. The method of claim 4 , wherein the processing comprises:

a separation process that separates intact cells from other components of the lysed mixture, the separation process comprising at least one of: filtration, centrifugation, and settling.

6. The method of claim 1 , wherein the subjecting comprises holding a batch of the mixture in a chamber that includes the acoustic standing wave field for a preset dwell time.

7. The method of claim 1 , wherein the subjecting comprises:

flowing the mixture through a chamber that includes the acoustic standing wave field.

8. The method of claim 1 , wherein the method further comprises lysing adipose cells of diameters equal to or greater than a second predetermined diameter that is smaller than the first predetermined diameter by:

generating a second acoustic standing wave field, wherein the geometry of the second acoustic standing wave field is such that one half of the wavelength of the second acoustic standing wave field is less than or equal to the second predetermined diameter, and wherein the intensity of the second acoustic standing wave field is sufficient to cause lysing of adipose cells of diameters equal to or greater than the second predetermined diameter; and

subjecting the lysed mixture to the second acoustic standing wave field, wherein the lysed mixture includes at least some adipose cells having a diameter equal to or greater than the second predetermined diameter.

9. A method for lysing adipose cells of diameters equal to or greater than a predetermined diameter, the method comprising:

generating an acoustic standing wave field, wherein the geometry of the acoustic standing wave field is such that one half of the wavelength of the acoustic standing wave field is less than or equal to the predetermined diameter, the wavelength of the acoustic standing wave field falling within a range of 0.5 mm to 2.5 mm, and wherein the intensity of the acoustic standing wave field is sufficient to cause lysing of adipose cells of diameters equal to or greater than the predetermined diameter; and

subjecting a mixture of adipose cells and stem cells to the acoustic standing wave field to generate a lysed mixture, wherein the mixture of adipose cells and stem cells includes at least some adipose cells having a diameter equal to or greater than the predetermined diameter.

10. The method of claim 9 , wherein the subjecting results in selective lysing of adipose cells equal to or greater than the predetermined diameter compared to cells of a smaller diameter.

11. The method of claim 9 , wherein the acoustic standing wave field is an ultrasonic standing wave field.

12. The method of claim 9 , further comprising:

processing the lysed mixture to prepare at least a portion of the lysed mixture for injection into a patient.

13. The method of claim 12 , wherein the processing comprises:

a separation process that separates intact cells from other components of the lysed mixture, the separation process comprising at least one of: filtration, centrifugation, and settling.

14. The method of claim 9 , wherein the subjecting comprises holding a batch of the mixture in a chamber that includes the acoustic standing wave field for a preset dwell time.

15. The method of claim 9 , wherein the subjecting comprises:

flowing the mixture through a chamber that includes the acoustic standing wave field.

16. The method of claim 9 , wherein the method further comprises lysing adipose cells of diameters equal to or greater than a second predetermined diameter that is smaller than the first predetermined diameter by:

generating a second acoustic standing wave field, wherein the geometry of the second acoustic standing wave field is such that one half of the wavelength of the second acoustic standing wave field is less than or equal to the second predetermined diameter, and wherein the intensity of the second acoustic standing wave field is sufficient to cause lysing of adipose cells of diameters equal to or greater than the second predetermined diameter; and

subjecting the lysed mixture to the second acoustic standing wave field, wherein the lysed mixture includes at least some adipose cells having a diameter equal to or greater than the second predetermined diameter.

Assignments (17)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
Reel/Frame 073654/0242 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
Reel/Frame 073654/0300 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
Reel/Frame 073637/0126 →
U.S. PATENT SECURITY AGREEMENT Recorded Jun 13, 2025
From: MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; BAUSCH HEALTH US, LLC (F/K/A VALEANT PHARMACEUTICALS NORTH AMERICA LLC); PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; BAUSCH HEALTH AMERICAS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 071564/0463 →
U.S. PATENT SECURITY AGREEMENT Recorded Jun 13, 2025
From: MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; BAUSCH HEALTH US, LLC (F/K/A VALEANT PHARMACEUTICALS NORTH AMERICA LLC); PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; BAUSCH HEALTH AMERICAS, INC.; SOLTA MEDICAL, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 071566/0200 →
SECURITY AGREEMENT (SECOND LIEN) Recorded Oct 5, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061606/0468 →
SECURITY AGREEMENT (FIRST LIEN) Recorded Oct 4, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061595/0066 →
SECURITY INTEREST Recorded Jun 13, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON
Reel/Frame 060346/0705 →
SECURITY AGREEMENT Recorded Feb 10, 2022
From: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 059121/0001 →
SECURITY INTEREST Recorded Jun 8, 2021
From: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 056811/0814 →
MERGER Recorded May 12, 2021
From: SOUND SURGICAL TECHNOLOGIES LLC
To: SOLTA MEDICAL, INC.
Reel/Frame 056214/0690 →
SECURITY INTEREST Recorded Mar 11, 2019
From: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 048556/0758 →
RELEASE OF SECURITY INTEREST IN PATENTS Recorded Jan 27, 2014
From: SILICON VALLEY BANK
To: SOUND SURGICAL TECHNOLOGIES LLC
Reel/Frame 032127/0587 →
RELEASE OF SECURITY INTEREST IN PATENTS Recorded Jan 27, 2014
From: CAPITAL ROYALTY PARTNERS II L.P.; CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.; PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
To: SOUND SURGICAL TECHNOLOGIES LLC
Reel/Frame 032127/0129 →
SHORT-FORM PATENT SECURITY AGREEMENT Recorded Nov 19, 2013
From: SOUND SURGICAL TECHNOLOGIES, LLC
To: CAPITAL ROYALTY PARTNERS II L.P.; CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.; PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
Reel/Frame 031674/0568 →
SECURITY AGREEMENT Recorded May 2, 2011
From: SOUND SURGICAL TECHNOLOGIES LLC
To: SILICON VALLEY BANK
Reel/Frame 026210/0237 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 21, 2011
From: SCHAFER, MARK E.
To: SOUND SURGICAL TECHNOLOGIES LLC
Reel/Frame 025988/0507 →